Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | EB103 |
| Synonyms | |
| Therapy Description |
EB103 comprises autologous T-lymphocytes engineered to express an antibody T-cell receptor (TCR) targeting CD19, as well as a co-stimulatory molecule comprising a CD19-targeted binding domain and human co-stimulatory receptor-derived domain, which potentially induces killing of tumor cells expressing CD19 (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| EB103 | EB 103|EB-103 | CD19 Immune Cell Therapy 72 | EB103 comprises autologous T-lymphocytes engineered to express an antibody T-cell receptor (TCR) targeting CD19, as well as a co-stimulatory molecule comprising a CD19-targeted binding domain and human co-stimulatory receptor-derived domain, which potentially induces killing of tumor cells expressing CD19 (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06343311 | Phase Ib/II | EB103 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (STARLIGHT-1) | Recruiting | USA | 0 |